Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    25

Stocks News & Analysis

stocks

Why we’ve downgraded this ASX software player

Morningstar lowers our fair value estimate for Megaport by 16% after mispricing leads to a downgrade in capital allocation rating.  
stocks

The market hates this compelling ASX income play

Santos continues to trade at a valuation that implies no growth in the years ahead. Our analyst Mark Taylor thinks that is misguided.
stocks

Lessons from the top performing ASX share

Chasing performance can lead to poor results but investors can still learn from top performers. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,754.7049.700.57%
CAC 407,255.4218.530.26%
DAX 4020,016.7583.130.42%
Dow JONES (US)44,729.2952.71-0.12%
FTSE 1008,359.4146.520.56%
HKSE19,746.32196.031.00%
NASDAQ19,470.9066.960.35%
Nikkei 22539,248.86735.841.91%
NZX 50 Index13,093.1821.50-0.16%
S&P 5006,050.783.630.06%
S&P/ASX 2008,495.2047.300.56%
SSE Composite Index3,378.8114.820.44%

Market Movers